[Collecting duct carcinoma and renal medullary carcinoma in the age of new therapies].
Tumeurs de Bellini et carcinomes médullaires rénaux à l’ère des nouvelles thérapies.
Antiangiogenic TKI
Carcinome des tubes collecteurs
Carcinome médullaire rénal
Collecting duct carcinoma
ITK anti-angiogénique
Immunotherapy
Immunothérapie
Renal medullary carcinoma
Journal
Bulletin du cancer
ISSN: 1769-6917
Titre abrégé: Bull Cancer
Pays: France
ID NLM: 0072416
Informations de publication
Date de publication:
Apr 2023
Apr 2023
Historique:
received:
01
11
2022
revised:
27
02
2023
accepted:
27
02
2023
medline:
31
3
2023
pubmed:
12
3
2023
entrez:
11
3
2023
Statut:
ppublish
Résumé
Collecting duct carcinoma (also known as Bellini tumour) and renal medullary carcinoma are two extremely rare and aggressive renal cancers. They are both less responsive to conventional treatments used in clear cell renal carcinoma. There are very few studies evaluating their optimal management and currently, at the metastatic stage, polychemotherapy based on platinum salts remains the most widely used. The emergence of new treatments such as anti-angiogenic TKIs, immunotherapy or treatments targeting specific genetic abnormalities, opens up a new field of possibilities in the management of these cancers. The evaluation of the response to these treatments is therefore essential. In this article, we will review the status of their management and the various studies that have evaluated recent treatments in these two cancers.
Identifiants
pubmed: 36906403
pii: S0007-4551(23)00102-9
doi: 10.1016/j.bulcan.2023.02.015
pii:
doi:
Types de publication
English Abstract
Journal Article
Review
Langues
fre
Sous-ensembles de citation
IM
Pagination
450-462Informations de copyright
Copyright © 2023 Société Française du Cancer. Published by Elsevier Masson SAS. All rights reserved.